BioNTech
The Latest
-
China To Receive First Foreign COVID-19 Vaccines From Germany's BioNTech
In return, Chinese citizens in Europe can be vaccinated with China's SinoVac, a German government spokesperson said 
In return, Chinese citizens in Europe can be vaccinated with China's SinoVac, a German government spokesperson said -
Cancer Vaccines Only A Few Years Away, BioNTech Founders Say
Within just eight years, the cancer vaccine might be readily accessible, said BioNTech co-founders Uğur Şahin and Özlem Türeci. Within just eight years, the cancer vaccine might be readily accessible, said BioNTech co-founders Uğur Şahin and Özlem Türeci. -
Moderna mRNA Patent Ignites Lawsuit Against Pfizer-BioNTech
Pfizer and BioNTech are being sued by Moderna for patents on life-saving technology that they claim to have filed years ago. 
Pfizer and BioNTech are being sued by Moderna for patents on life-saving technology that they claim to have filed years ago. -
COVID-19 Vaccines For Young Children Could Roll Out 'In Earnest' June 21, White House Says
Pfizer and its partner BioNTech on Wednesday completed their filing with the U.S. FDA to seek authorization for their COVID-19 vaccine in young children. 
Pfizer and its partner BioNTech on Wednesday completed their filing with the U.S. FDA to seek authorization for their COVID-19 vaccine in young children. -
Pfizer Pill Becomes First COVID-19 Treatment Approved By FDA
Paxlovid, produced by Pfizer, was shown in clinical trials to reduce the chance of severe sickness by 90%. 
Paxlovid, produced by Pfizer, was shown in clinical trials to reduce the chance of severe sickness by 90%. -
U.S. FDA Could Authorize COVID-19 Anti-Viral Treatment This Week
Both pills are administered as at-home treatment for those with a higher risk of getting COVID-19. Both pills are administered as at-home treatment for those with a higher risk of getting COVID-19. -
Pfizer's COVID-19 Immunity Protection Drops After Two Months -- Study
A 90% success rate was observed after Pfizer's second dose of prevention against hospitalization and death. 
A 90% success rate was observed after Pfizer's second dose of prevention against hospitalization and death. -
Pfizer COVID-19 Vaccine Loses Effectiveness Over Time, Scientists Say
The vaccine's efficacy in preventing hospitalization and death remained high for at least six months, researchers say. 
The vaccine's efficacy in preventing hospitalization and death remained high for at least six months, researchers say. -
Joe Biden Receives His COVID-19 Booster On Camera
The CDC and the FDA backed a booster shot of Pfizer's vaccine last week for individuals 65 years and older. 
The CDC and the FDA backed a booster shot of Pfizer's vaccine last week for individuals 65 years and older. -
Pfizer CEO Predicts Life 'Back To Normal' Within A year
Pfizer's stock price climbed from $30.99 on March 8, 2020 to $43.94 on Monday. 
Pfizer's stock price climbed from $30.99 on March 8, 2020 to $43.94 on Monday.
